• 1
    Non-Small Cell Lung Cancer Collaborative Groups. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ. 1995; 311: 899909.
  • 2
    Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004; 22: 330353.
  • 3
    D'Addario G, Pintilie M, Leighl NB, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol. 2005; 23: 29262936.
  • 4
    Paccagnella A, Favaretto A, Oniga F, et al. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized Phase III trial. Lung Cancer. 2004; 43: 8391.
  • 5
    Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol. 2002; 13: 15391549.
  • 6
    Mazzanti P, Massacesi C, Rocchi MB, et al. Randomized, multicenter, Phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2003; 41: 8189.
  • 7
    Zatloukal P, Petruzelka L, Zemanova M, et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in Stage IIIb and IV non-small cell lung cancer: a Phase III randomized trial. Lung Cancer. 2003; 41: 321331.
  • 8
    Sederholm C, Hillerdal G, Lamberg K, et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol. 2005; 23: 83808388.
  • 9
    Katakami N, Sugiura T, Nogami T, et al. Combination chemotherapy of gemcitabine and vinorelbine for patients in Stage IIIB-IV non-small cell lung cancer: a Phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908. Lung Cancer. 2004; 43: 93100
  • 10
    Gridelli C, Gallo C, Shepherd FA, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a Phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003; 21: 30253034.
  • 11
    Laack E, Dickgreber N, Muller T, et al. Randomized Phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol. 2004; 22: 23482356.
  • 12
    Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989; 7: 17481756.
  • 13
    Gault MH, Longerich LL, Harnett JD, et al. Predicting glomerular function from adjusted serum creatinine. Nephron. 1992; 62: 249256.
  • 14
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205216.
  • 15
    Rudd RM, Gower NH, Spiro SG, et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with Stage IIIB or IV non-small-cell lung cancer: a Phase III randomized study of the London Lung Cancer Group. J Clin Oncol. 2005; 23: 142153.
  • 16
    Alberola V, Camps C, Provencio M, et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group Phase III randomized trial. J Clin Oncol. 2003; 21: 32073213.
  • 17
    Gandara DR, Ohe Y, Kubota K, et al. Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): a model for prospective comparison of cooperative group trials. Proc Am Soc Clin Oncol. 2004; 23: 616. Abstract 7007.